Stepping down therapy in COPD
JJ Reilly - New England Journal of Medicine, 2014 - Mass Medical Soc
Patients with symptomatic chronic obstructive pulmonary disease (COPD) are commonly
treated with inhaled medications that fall into three classes: beta-agonists, muscarinic …
treated with inhaled medications that fall into three classes: beta-agonists, muscarinic …
Meta-analysis: anticholinergics, but not β-agonists, reduce severe exacerbations and respiratory mortality in COPD
SR Salpeter, NS Buckley, EE Salpeter - Journal of general internal …, 2006 - Springer
BACKGROUND: Anticholinergics and β2-agonists have generally been considered
equivalent choices for bronchodilation in chronic obstructive pulmonary disease (COPD) …
equivalent choices for bronchodilation in chronic obstructive pulmonary disease (COPD) …
[PDF][PDF] Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two-in-one inhaler versus separate …
E Chrischilles, D Gilden, J Kubisiak… - Am J Manag …, 2002 - researchgate.net
Objective: To determine whether a combined formulation consisting of ipratropium and an
inhaled β2 agonist (2-in-1 therapy) leads to lower respiratory-related healthcare use and …
inhaled β2 agonist (2-in-1 therapy) leads to lower respiratory-related healthcare use and …
Relationship between improved airflow limitation and changes in airway calibre induced by inhaled anticholinergic agents in COPD
M Hasegawa, H Makita, Y Nasuhara, N Odajima… - Thorax, 2009 - thorax.bmj.com
Background: Although airflow limitation improved by inhaled anticholinergic drugs varies
among individuals with chronic obstructive pulmonary disease (COPD), the relationship …
among individuals with chronic obstructive pulmonary disease (COPD), the relationship …
Cardiovascular mortality and morbidity in chronic obstructive pulmonary disease: the impact of bronchodilator treatment
R Wood‐Baker, B Cochrane… - Internal Medicine …, 2010 - Wiley Online Library
Chronic obstructive pulmonary disease (COPD) is a substantial health burden.
Cardiovascular disease (CVD), the leading cause of death, frequently coexists with COPD …
Cardiovascular disease (CVD), the leading cause of death, frequently coexists with COPD …
A randomized trial of dual-acting bronchodilator AZD8871 for chronic obstructive pulmonary disease
D Singh, R Fuhr, L Jimenez… - American Journal of …, 2019 - atsjournals.org
Long-acting bronchodilators are recommended as maintenance therapy for chronic
obstructive pulmonary disease (COPD)(1). Dual therapy using long-acting muscarinic …
obstructive pulmonary disease (COPD)(1). Dual therapy using long-acting muscarinic …
Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled …
CV Asche, S Leader, C Plauschinat… - … journal of chronic …, 2012 - Taylor & Francis
Background To estimate the potential cost savings by following the current Global Initiative
for Chronic Obstructive Lung Disease (GOLD) guideline recommendations in patients being …
for Chronic Obstructive Lung Disease (GOLD) guideline recommendations in patients being …
Regular versus as-needed short-acting inhaled β-agonist therapy for chronic obstructive pulmonary disease
Regular short-acting inhaled β-agonist therapy is of uncertain benefit in patients with chronic
obstructive pulmonary disease (COPD). We conducted a randomized, concealed, double …
obstructive pulmonary disease (COPD). We conducted a randomized, concealed, double …
[HTML][HTML] Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting β2-agonists in a health maintenance …
YM Gagnon, AR Levy, MD Spencer, JS Hurley… - Respiratory …, 2005 - Elsevier
OBJECTIVES: In light of recent results from observational studies showing prolonged
survival in subjects taking long-acting β2-agonists (LABA) and/or inhaled corticosteroids …
survival in subjects taking long-acting β2-agonists (LABA) and/or inhaled corticosteroids …
Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI
ER Sutherland, S Brazinsky, G Feldman… - … medical research and …, 2009 - Taylor & Francis
Objective: Bronchodilator maintenance treatment improves pulmonary function and health-
related quality of life in COPD patients. Pulmonary function and patient …
related quality of life in COPD patients. Pulmonary function and patient …